Holen Sie sich die Stockscreener-App
46.70
4.17%
1.87
Handel nachbörslich:
46.70
Schlusskurs vom Vortag:
$44.83
Offen:
$44.54
24-Stunden-Volumen:
994.02K
Relative Volume:
2.12
Marktkapitalisierung:
$2.65B
Einnahmen:
$29.40M
Nettoeinkommen (Verlust:
$-352.62M
KGV:
-11.82
EPS:
-3.95
Netto-Cashflow:
$-318.99M
1W Leistung:
-0.28%
1M Leistung:
+13.01%
6M Leistung:
+35.21%
1J Leistung:
+107.65%
1-Tages-Spanne:
$43.25
$46.79
1-Wochen-Bereich:
$43.25
$47.21
52-Wochen-Spanne:
$20.40
$53.28
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan
Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat
Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com
Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate
Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com
Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Earnings Preview: Agios Pharmaceuticals - Benzinga
Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat
Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St
Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat
Pfizer Pulls Key Sickle Cell Drug Over Safety Concerns - Finimize
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia
Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India
Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online
Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada
Agios completes enrollment for sickle cell disease trial - Investing.com
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
(AGIO) Investment Report - Stock Traders Daily
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - StockTitan
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - GlobeNewswire Inc.
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by StockNews.com to Hold - MarketBeat
Scotiabank Initiates Coverage on Agios Pharmaceuticals (NASDAQ:AGIO) - MarketBeat
Beta Thalassemia Market to Show Remarkable Growth Trends from - openPR
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update - MarketBeat
Leerink keeps market perform rating on Agios Pharma shares amid SCD drug concerns - Investing.com Canada
SG Americas Securities LLC Invests $705,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? - MSN
AQR Capital Management LLC Increases Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharma stock raised to Outperform By Investing.com - Investing.com UK
4 Analysts Have This To Say About Agios Pharmaceuticals - Benzinga
Raymond James Reiterates Outperform Rating for Agios Pharmaceuticals (NASDAQ:AGIO) - MarketBeat
Sei Investments Co. Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
The Manufacturers Life Insurance Company Has $5.94 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma - Barchart
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jones Cecilia | Chief Financial Officer |
Sep 26 '24 |
Sale |
49.03 |
2,542 |
124,634 |
20,158 |
| Ballal Rahul D. | Director |
Aug 11 '24 |
Option Exercise |
0.00 |
2,302 |
0 |
7,992 |
| Smith Cynthia | Director |
Aug 11 '24 |
Option Exercise |
0.00 |
2,302 |
0 |
7,992 |
| Goff Brian | Chief Executive Officer |
Aug 08 '24 |
Option Exercise |
0.00 |
22,691 |
0 |
89,883 |
| Goff Brian | Chief Executive Officer |
Aug 08 '24 |
Sale |
42.75 |
11,091 |
474,140 |
78,792 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):